Literature DB >> 16501927

Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre.

G Golini1, G Cazzola, R Fontana.   

Abstract

In order to further understanding of how different isolates of Burkholderia cepacia complex persist, spread and cause disease, B. cepacia-complex isolates from 60 patients attending the Cystic Fibrosis Centre of Verona, Italy, between 1997 and 2002 were analyzed. Strains were examined for species, presence of putative epidemic and virulence markers (i.e., cblA and the B. cepacia epidemic-strain marker [BCESM]), genetic relatedness and antibiotic susceptibility. Forty-five percent of patients were infected with B. cenocepacia recA subgroup B, 28% with B. cenocepacia recA subgroup A, 5% with B. multivorans and 5% with B. cepacia. No isolate carried cblA but 35% of B. cenocepacia and one of B. cepacia carried the BCESM transmissibility marker. Pulsed-field gel electrophoresis (PFGE) identified 40 types; 22 of these corresponded to sporadic isolates and 18 to clusters of identical or genetically related strains. Piperacillin, ceftazidime and piperacillin-tazobactam were the most active antibiotics (43.3, 31.1 and 35.5% of resistance, respectively). These results confirm the prevalence of B. cenocepacia in cystic fibrosis patients with rapid clinical deterioration and in those with stable cases of infection. The rates of multiple-source and cross infection were relatively low.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501927     DOI: 10.1007/s10096-006-0099-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.

Authors:  J J LiPuma; T Spilker; L H Gill; P W Campbell; L Liu; E Mahenthiralingam
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom.

Authors:  F E Clode; M E Kaufmann; H Malnick; T L Pitt
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Molecular characterization of Burkholderia cepacia isolates from cystic fibrosis (CF) patients in an Italian CF center.

Authors:  Andrea Petrucca; Paola Cipriani; Piera Valenti; Daniela Santapaola; Carmen Cimmino; Gian Luca Scoarughi; Iolanda Santino; Stefania Stefani; Rosa Sessa; Mauro Nicoletti
Journal:  Res Microbiol       Date:  2003-09       Impact factor: 3.992

6.  Molecular epidemiology of cystic fibrosis-linked Burkholderia cepacia complex isolates from three national referral centres in Ireland.

Authors:  D Crowley; M Daly; B Lucey; P Shine; J J Collins; B Cryan; J E Moore; P Murphy; G Buckley; S Fanning
Journal:  J Appl Microbiol       Date:  2002       Impact factor: 3.772

7.  Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.

Authors:  Tom Coenye; Theodore Spilker; Alissa Martin; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  Genomovar diversity amongst Burkholderia cepacia complex isolates from an Australian adult cystic fibrosis unit.

Authors:  T J Kidd; S C Bell; C Coulter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-27       Impact factor: 3.267

9.  Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.

Authors:  T L Pitt; M E Kaufmann; P S Patel; L C Benge; S Gaskin; D M Livermore
Journal:  J Med Microbiol       Date:  1996-03       Impact factor: 2.472

10.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  7 in total

1.  Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center.

Authors:  J H Leitão; S A Sousa; M V Cunha; M J Salgado; J Melo-Cristino; M C Barreto; I Sá-Correia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-04       Impact factor: 3.267

2.  Activity of Aerosolized Levofloxacin against Burkholderia cepacia in a Mouse Model of Chronic Lung Infection.

Authors:  Mojgan Sabet; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center.

Authors:  Priscila Dentini; Fernando Augusto Lima Marson; Luciana Cardoso Bonadia; Carmen Sílvia Bertuzzo; Antônio Fernando Ribeiro; Carlos Emílio Levy; José Dirceu Ribeiro
Journal:  Med Microbiol Immunol       Date:  2017-09-30       Impact factor: 3.402

4.  Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain.

Authors:  M J Medina-Pascual; S Valdezate; P Villalón; N Garrido; V Rubio; J A Saéz-Nieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-02       Impact factor: 3.267

5.  Structural stability of Burkholderia cenocepacia biofilms is reliant on eDNA structure and presence of a bacterial nucleic acid binding protein.

Authors:  Laura A Novotny; Amal O Amer; M Elizabeth Brockson; Steven D Goodman; Lauren O Bakaletz
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

6.  Crystal structures of Burkholderia cenocepacia dihydropteroate synthase in the apo-form and complexed with the product 7,8-dihydropteroate.

Authors:  Rachel E Morgan; Gaëlle O Batot; Jennifer M Dement; Vincenzo A Rao; Thomas C Eadsforth; William N Hunter
Journal:  BMC Struct Biol       Date:  2011-05-09

7.  Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity.

Authors:  William R Schwan; Craig Dunek; Michael Gebhardt; Kathleen Engelbrecht; Tiffany Klett; Aaron Monte; Joseph Toce; Marc Rott; Thomas J Volk; John J LiPuma; Xue-Ting Liu; Ronald McKelvey
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-21       Impact factor: 3.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.